Biogen INC BIOGEN INC ORD SHS
Biogen INC BIOGEN INC ORD SHS/ US09062X1037 /
0R1B
24/05/2024 18:25:10
|
Chg.
-
|
Volume |
Bid06:00:09 |
Demandez à06:00:09 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
218.75USD
|
-
|
1,014 Chiffrre d'affaires: 110,398.48 |
-Bid taille: - |
-Ask la taille: - |
29.83 Mrd.USD |
- |
25.53 |
Description de l'entreprise
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Conseil d'administration & Conseil de surveillance
PDG |
Christopher A. Viehbacher |
Conseil d'administration |
Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal |
Conseil de surveillance |
Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher |
Données de l'entreprise
Nom: |
Biogen Inc. |
Adresse: |
225 Binney Street,Cambridge, Massachusetts 02142, USA |
Téléphone: |
+1 781-464-2000 |
Fax: |
+1-617-679-2617 |
Courriel: |
-
|
Internet: |
www.biogen.com |
Industrie: |
Biotechnology |
Secteur: |
Biotechnology |
Sous-secteur: |
Biotechnology |
Fin de l'exercice financier: |
31/12 |
Flotte libre: |
72.20% |
IPO date: |
- |
Relations avec les investisseurs
Nom: |
Karen Jewell |
Téléphone IR: |
781-464-2442 |
IR-Fax: |
- |
E-mail IR: |
IR@biogenidec.com
|
Principaux actionnaires
Autres |
|
48.93% |
PRIMECAP MANAGEMENT CO CA |
|
11.17% |
Vanguard Group |
|
9.90% |
BlackRock Inc. |
|
9.79% |
State Street Corporation |
|
4.77% |
"T. Rowe Price Investment Management, Inc." |
|
3.68% |
Wellington Management Group |
|
3.66% |
JP Morgan Chase & Co. |
|
3.44% |
GEODE CAPITAL MANAGEMENT LLC |
|
2.27% |
Autres |
|
2.40% |